Figure 2. Kaplan-Meier curves showing the association between overall survival and pre-treatment miR-345 expression in whole blood from patients with metastatic colorectal cancer treated with 3rd line cetuximab and irinotecan.
(A) Patients were dichotomized by KRAS mutation status and miR-345. (B) Patients were dichotomized by BRAF wt mutations status and miR-345. (C) Patients were dichotomized by PI3KCA mutation status and miR-345. (D) Patients were dichotomized by double wt mutation status and miR-345. The P-value refers to the Wald test.